Our consultancy firm’s publication | CEPTON Strategies
Colloque France Biotech, le 7 juin 2012. Molecular diagnostics is the key to personalized medicine. In that respect, it has a promising future. However, the regulatory and market access landscapes are still fragmented and lack a clear framework. Many barriers still remain today. CEPTON has spoken at France Biotech’s congress on this topic in Paris, on June 7, 2012.
Request the full study by using our contact formular.
